Latest Conference

Deb York, PMHNP-BC, sheds light on postpartum psychiatry at the conference.

The Chair of the Southern California Psychiatry Conference offers his favorite take home points on schizophrenia and M1-M4 agonists that can be found in the initial sessions.

Brush up on your reading before you attend the Southern California Psychiatry Conference!

An interdisciplinary gathering at the 2025 virtual conference of the Society for Digital Mental Health heard presentations and panel discussions on digital therapeutics, along with reports of studies on the technology and outcomes by student and young researchers.

Discover key insights from the APA Annual Meeting, highlighting advancements in lifestyle psychiatry, ADHD treatment, and innovative suicide prevention models.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

Cariprazine shows promise as a long-term adjunctive treatment for anhedonia in major depressive disorder, according to new poster data presented at the ASCP Annual Meeting.

Neurocrine Biosciences reveals promising phase 2 results for NBI-1117568, a novel treatment for schizophrenia, showing significant symptom improvement over placebo.

Vincenzo Di Nicola discusses the importance of pluralism in social psychiatry and the need for culturally relevant psychotherapy at the 2025 APA Annual Meeting.

Psychiatrists united in Los Angeles for a rally, advocating for mental health funding amidst growing concerns over service cuts and societal challenges.

Phillip R. Muskin, MD, discusses the complexities of prescribing antipsychotics, emphasizing patient collaboration and the importance of evaluating treatment strategies.

Dr Goldberg and Dr Anita share previews of the upcoming ASCP Annual Meeting in Scottsdale, Arizona.

Take a look at innovative GSK-3β inhibitors to enhance efficacy and reduce adverse effects seen in lithium with Jonathan M. Meyer, MD, DLFAPA, at the 2025 APA Annual Meeting.

How many apps do you use on your phone? John Luo, MD, a technology expert shares his thoughts on their usefulness at the 2025 APA Annual Meeting.

Ketamine-assisted psychotherapy: enhancing healing through emotional support and insight-driven therapy for depression.

Psychiatry must embrace media to combat misinformation, shared Mena Mirhom, MD, FAPA, at the 2025 APA Annual Meeting.

Will AI replace psychiatrists and mental health clinicians? John Luo, MD, thinks not, despite the many technological advances of today.

Badr Ratnakaran, MBBs, highlights the rising stressors for older adults, emphasizing the urgent need for improved health care and support systems.

Fathers share their heartbreaking stories of loss and advocate for a new model of suicide prevention that emphasizes early intervention and awareness at the 2025 APA Annual Meeting.

Discover how insulin influences mood and cognition, revealing new therapeutic possibilities for depression and bipolar disorder, in this discussion with Roger McIntyre, MD, FRCPC, at the 2025 APA Annual Meeting.

Experts discuss groundbreaking insights on ketamine's role in treating depression, highlighting its rapid effects and potential to transform psychopharmacology.

Why was this year's APA Annual Meeting historic? H. Steven Moffic, MD, shares his thoughts.

How does adult ADHD differ from pediatric ADHD? Jeffrey Newcorn, MD, shared his expertise at the 2025 APA Annual Meeting.

The APA Annual Meeting: a valuable career opportunity.

At the APA Annual Meeting, John Luo, MD, discussed the importance of managing your online reputation and privacy in today's digital landscape for future opportunities.

Antipsychotic plasma levels play a critical role of in treatment decisions. Learn more in this conversation from the 2025 APA Annual Meeting.

Ramaswamy Viswanathan, MD, DrMedSc, emphasizes the vital role of lifestyle in mental health treatment and advocates for holistic approaches to prevent premature death at the 2025 APA Annual Meeting.